Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Cytokinetics Inc., consolidated income statement (quarterly data)

US$ in thousands

3 months ended:	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018
Research and development revenues	378)	867)	2,113)	1,957)	2,515)	968)	1,148)	744)	437)	2,843)	6,548)	3,922)	5,187)	3,593)	3,825)	5,212)	6,055)	7,137)	8,464)	9,377)	8,726)	4,680)	3,585)
License revenues	—)	—)	—)	—)	—)	—)	—)	54,856)	—)	—)	—)	—)	36,501)	—)	—)	—)	—)	—)	—)	—)	1,915)	1,535)	1,683)
Milestone revenues	—)	—)	2,500)	—)	—)	1,000)	—)	—)	5,000)	—)	—)	2,800)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Realization of revenue participation right purchase agreement	—)	—)	—)	—)	—)	87,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Revenues	378)	867)	4,613)	1,957)	2,515)	88,968)	1,148)	55,600)	5,437)	2,843)	6,548)	6,722)	41,688)	3,593)	3,825)	5,212)	6,055)	7,137)	8,464)	9,377)	10,641)	6,215)	5,268)
Research and development	(82,532)	(83,194)	(79,421)	(75,018)	(62,734)	(57,126)	(45,935)	(43,498)	(48,436)	(36,443)	(31,561)	(29,221)	(24,202)	(21,790)	(21,738)	(18,334)	(20,229)	(24,017)	(23,545)	(24,027)	(21,391)	(21,582)	(22,135)
General and administrative	(40,111)	(39,722)	(49,665)	(53,969)	(48,222)	(42,716)	(33,070)	(33,806)	(26,202)	(21,197)	(15,598)	(13,908)	(12,302)	(14,161)	(12,449)	(10,584)	(9,753)	(9,836)	(9,437)	(6,808)	(7,164)	(8,046)	(9,264)
Operating expenses	(122,643)	(122,916)	(129,086)	(128,987)	(110,956)	(99,842)	(79,005)	(77,304)	(74,638)	(57,640)	(47,159)	(43,129)	(36,504)	(35,951)	(34,187)	(28,918)	(29,982)	(33,853)	(32,982)	(30,835)	(28,555)	(29,628)	(31,399)
Operating income (loss)	(122,265)	(122,049)	(124,473)	(127,030)	(108,441)	(10,874)	(77,857)	(21,704)	(69,201)	(54,797)	(40,611)	(36,407)	5,184)	(32,358)	(30,362)	(23,706)	(23,927)	(26,716)	(24,518)	(21,458)	(17,914)	(23,413)	(26,131)
Interest expense	(7,136)	(7,045)	(6,961)	(7,057)	(6,804)	(2,807)	(2,746)	(4,218)	(4,161)	(4,073)	(3,988)	(4,018)	(3,976)	(3,892)	(4,077)	(2,731)	(1,345)	(1,377)	(1,170)	(1,169)	(867)	(898)	(863)
Loss on settlement of debt	—)	—)	—)	—)	(22,246)	—)	(2,693)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(6,860)	(6,322)	(6,280)	(9,212)	(8,963)	(7,003)	(6,564)	(4,271)	(2,955)	(2,871)	(2,795)	(5,651)	(5,461)	(5,912)	(5,689)	(5,533)	(5,321)	(5,064)	(4,819)	(4,741)	(4,559)	(4,338)	(4,129)
Interest and other income, net	6,839)	6,779)	6,425)	5,919)	4,144)	864)	415)	(377)	231)	187)	290)	2,146)	1,078)	1,382)	723)	1,330)	1,020)	1,044)	1,141)	900)	1,323)	1,126)	842)
Loss, before income tax provision	(129,422)	(128,637)	(131,289)	(137,380)	(142,310)	(19,820)	(89,445)	(30,570)	(76,086)	(61,554)	(47,104)	(43,930)	(3,175)	(40,780)	(39,405)	(30,640)	(29,573)	(32,113)	(29,366)	(26,468)	(22,017)	(27,523)	(30,281)
Income tax provision	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Net loss	(129,422)	(128,637)	(131,289)	(137,380)	(142,310)	(19,820)	(89,445)	(30,570)	(76,086)	(61,554)	(47,104)	(43,930)	(3,175)	(40,780)	(39,405)	(30,640)	(29,573)	(32,113)	(29,366)	(26,468)	(22,017)	(27,523)	(30,281)

Download chart

Income statement item	Description	The company
Revenues	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Cytokinetics Inc. revenues decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Operating income (loss)	The net result for the period of deducting operating expenses from operating revenues.	Cytokinetics Inc. operating income (loss) increased from Q1 2023 to Q2 2023 but then slightly decreased from Q2 2023 to Q3 2023.
Loss, before income tax provision	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Cytokinetics Inc. loss, before income tax provision increased from Q1 2023 to Q2 2023 but then slightly decreased from Q2 2023 to Q3 2023.
Net loss	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Cytokinetics Inc. net loss increased from Q1 2023 to Q2 2023 but then slightly decreased from Q2 2023 to Q3 2023.

Cytokinetics Inc. (NASDAQ:CYTK)

Income Statement Quarterly Data

Income Statement
Quarterly Data